Understanding response and resistance to inhibition of mutant isocitrate dehydrogenase in acute myeloid leukaemia

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1099160

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Acute myeloid leukaemia (AML) is an aggressive cancer of white blood cells and development of novel treatment options is urgently needed. Mutations in enzymes known as isocitrate dehydrogenase (IDH) -1 and -2 are amongst the most common in AML and recent studies strongly suggest that mutant IDH proteins are attractive drug targets. In this proposal we will use advanced genetic tools to comprehensively analyse the role of IDH dysfunction in leukaemia initiation, development and progression.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $581,979.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

acute myeloid leukaemia (AML) | anticancer drug | cancer biology | epigenetics | mouse models

Related Links